NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany

CompletedN/A

Sponsor: Novartis Pharmaceuticals

Conditions: Gastro-enteropancreatic Neuroendocrine Tumor

Countries: Germany

The aim of this study was to assess patient characteristics and treatment patterns of gastro-enteropancreatic neuroendocrine tumor (GEP-NET) patients who received PRRT in German routine care.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion criteria:

* Patients with a confirmed diagnosis of GEP-NET (any localization of the primary tumor including cancer of unknown primary origin \[CUP\], any Grade).
* Patients with a first cycle of primary PRRT of home-brew 177Lu-DOTATATE/DOTATOC or Lutathera® between 01 July 2020 and 30 June 2021.

Exclusion criteria:

* Received a combination of PRRT with chemotherapy.
* Received a combination of PRRT with a radionuclide other than lutetium-177 (e.g., yttrium-90).

Locations (7)

Essen, Germany
Heidelberg, Germany
München, Germany
Rostock, Germany
Stuttgart, Germany
Tübingen, Germany
Würzburg, Germany